Ignite Creation Date:
2024-07-17 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06482554
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-06-26
Brief Title:
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms
Sponsor:
Louisiana State University Health Sciences Center Shreveport
Organization:
Louisiana State University Health Sciences Center Shreveport
Study Overview
Official Title:
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy Apathy Evaluation Scale - Clinician - Apathy assessment and to examine a possible correlation between improvement in apathy scores and changes in elements of the PANSS Positive and Negative Syndrome Scale due to treatment with Lumateperone
Detailed Description:
1 To determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy assessment
2 To examine a possible correlation between improvement in apathy scores and changes in elements of the PANSS Positive and Negative Syndrome Scale due to treatment with Lumateperone
2 To examine a possible correlation between improvement in apathy scores and changes in elements of the PANSS Positive and Negative Syndrome Scale due to treatment with Lumateperone
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None